Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium

Author(s):  Jones Marty

Issue:  Jan/Feb 2000 - Compounding for Pain Management
View All Articles in Issue

Page(s):  6-15

Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 1
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 2
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 3
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 4
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 5
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 6
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 7
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 8
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 9
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 10

Download in electronic PDF format for $75

Abstract:  Recent reports of N-methyl-D-aspartate receptor antagonists, glutamate antagonists, alpha2-agonists, gamma-aminobutyric acid agonists, alpha1-antagonists, opioids and antioxidants in various combinations provide the contemporary rationale that is furnishing increased efficacy in the clinical management of chronic neuropathic pain, with fewer side effects. This article focuses on this new theory as an approach, from the perspective of a compounding pharmacist, to provide better control of chronic neuropathic pain in the new millennium. Implementation of this theory in daily practice within the triad of care will enhance the odds of positive outcomes in patients suffering from chronic neuropathic pain. The author focuses on pathophysiology, evidence, a new approach and clinical compounding success. He concludes that this is a huge market and that the efficacy is significant using the approach presented in this article.

Related Keywords: allodynia, amantadine, AMPA receptors, baclofen, carbamazepine, clonidine, compounding, DermiGel, dermis, dextromethorphan, diabetic peripheral neuropathy, epidermis, fibromyalgia, free radicals, GABA receptors, gapabentin, HbA1c, hyperalgesia, ketamine, memantine, neuropathic pain, nifedipine, NMDA receptors, opioids, opium, orphenadrine, pain, pain management, phenytoin, PLO, postherpetic neuralgia, prazosin, reflex sympathetic dystrophy, speed gel, tricyclic antidepressants, valproic acid, VanPen, dermatome

Related Categories: MENTAL HEALTH, PAIN MANAGEMENT

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium
Jones Marty
Jan/Feb 2000
Pg. 6-15

Profile of a Practice: Ward Drug Company Diabetic Shoppe and Prescription Compounding Center
Vail Jane
Jan/Feb 2003
Pg. 21-23

Clinical Nuggets and Pearls: Chronic Neuropathic Pain and Opioid Tolerance
Jones Marty
Jan/Feb 2002
Pg. 4-6

Transdermal Gels in the Treatment of Diabetic Neuropathy
Hodges Caroline J
, Jones Thomas H, Willoughby David L
Mar/Apr 2000
Pg. 91-93

Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott
, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
May/Jun 2010
Pg. 182-192

Case Report: Wound Care of a Diabetic Foot Ulcer
Wynn Tom
Jul/Aug 2004
Pg. 265-267

Compounding Pearls -- Wound Care: Diabetic Foot Ulcers, Part 1
Riepl Mike
May/Jun 2020
Pg. 182-186

Topical Medications for Orofacial Neuropathic Pain
Bramwell Bethany L
May/Jun 2010
Pg. 200-203

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Mar/Apr 2024
Pg. 100-109

Levorphanol for the Treatment of Severe Chronic Pain
McNulty Jack P
May/Jun 2007
Pg. 202-211

Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji
, Sumanasekera Wasana, Le Uyen Minh
Jan/Feb 2022
Pg. 65-71

Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm
Allen Loyd V Jr
May/Jun 2016
Pg. 231

PostScription: Treatment of Chronic Pain with Methadone or Levorphanol
McNulty Jack P
Mar/Apr 2006
Pg. 159-160

Update on Managing Neuropathic Pain
McNulty Jack P
, Muller George
May/Jun 2009
Pg. 182-190

Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm
Allen Loyd V Jr
Mar/Apr 2024
Pg. 135

The Role of Sex Hormones on Fibromyalgia Pain Mediators
Bramwell Bethany L
May/Jun 2010
Pg. 193-199

The Clinical Pharmacist's Role in Compounding for the Diabetic Patient
Harshbarger Robert
, Harshbarger Diana
Mar/Apr 2000
Pg. 84-87

Complications of Diabetes
Key David M
Mar/Apr 2000
Pg. 88-90

Dextromethorphan, an NMDA receptor antagonist, as a Treatment for Pain
Mishkan Emilyn S
Sep/Oct 2005
Pg. 339-346

Return to Top